--- title: "Most Healthcare AI Pilots Never Reach Production — It Is an Architecture Problem" slug: "healthcare-ai-pocs-fail-architecture-not-model" author: "Jaione Amigot" date: "2026-08-24 17:30:00" category: "Premium" topics: "healthcare AI, health insurers, HIPAA, AI architecture, structured outputs, model evaluation, audit logging, payer AI" summary: "Roughly four in five healthcare AI pilots never reach production, and the cause is rarely the model. What separates the survivors is architecture: structured outputs, deterministic fallbacks, domain-specific evaluation and audit-complete observability — none of which a demo needs and all of which production requires." banner: "" thumbnail: "" linkedin: | Roughly 4 in 5 healthcare AI pilots never reach production. IDC's 2025 survey put it more starkly: for every 33 AI pilots launched, 4 shipped. Talk to engineers deploying inside US health insurers and the diagnosis is consistent — and it is almost never the model. What actually kills a payer AI pilot: → Free-text output where the receiving system needs a schema. A claims pipeline cannot consume a paragraph. → No deterministic fallback. When the model is unavailable or low-confidence, the process must still complete — a human queue is a valid answer, a silent failure is not. → Generic benchmarks instead of domain evaluation. MMLU tells you nothing about prior-authorization accuracy. → Observability that cannot survive an audit. If you cannot reconstruct which model, which version, which prompt and which data produced a determination, it does not pass review. None of these are visible in a demo. All of them are load-bearing in production. That is why the demo-to-production gap is an architecture gap. On ibl.ai you own all the code and the data, run it model-agnostic across any LLM, and pay with no per-seat pricing — so PHI stays inside your perimeter and the audit trail belongs to you, not to a vendor's log retention policy. #iblai #HealthcareAI #EnterpriseAI #HIPAA #AIArchitecture --- ## The Short Answer **Roughly four in five healthcare AI pilots never reach production, and the failure is architectural rather than a model-quality problem. On ibl.ai you own all the code and the data, run it model-agnostic across any LLM, and pay with no per-seat pricing — so PHI stays inside your perimeter, the audit trail is yours rather than a vendor's, and the four things that decide whether a pilot ships are properties you control rather than features you hope a vendor exposes.** The figure is consistent across sources. Analyses drawing on RAND and McKinsey work put healthcare AI pilot failure near [80%](https://healthtechdigital.com/the-ai-implementation-gap-why-80-of-healthcare-ai-projects-fail-to-scale-beyond-pilot-phase/); IDC's 2025 global survey found that for every 33 AI pilots launched, only 4 reached production. ## Why do healthcare AI pilots fail if the models are good enough? Because a demo and a production system are asked different questions. A demo is asked: can the model produce a plausible answer to this input? Modern models pass that easily, which is why pilots are so often declared successful. Production is asked: can this run 40,000 times a day, inside a claims workflow, with a defensible record of every determination, and degrade safely when something breaks? Nothing in the first question prepares you for the second. That gap is where pilots die — not in model selection, but in everything between the model and the system of record. The commonly cited causes are integration readiness, governance and operational fit rather than accuracy, and hospitals routinely spend six figures on pilots that never clear compliance review. ## What are the four properties that separate shipped systems from dead pilots? Engineers who have taken AI into production inside payers tend to converge on the same short list. ### Structured outputs, not free text A claims-adjudication pipeline, a prior-authorization queue and an eligibility check all consume records, not prose. If the model returns a paragraph, something downstream must parse it — and that parser becomes the least reliable component in the system. Constrain the model to a schema and validate against it. A response that fails validation is a caught error. A paragraph that gets misparsed is a silent one, and silent errors in a payer workflow surface as denials somebody has to appeal. ### Deterministic fallbacks The model will be unavailable, rate-limited, or below confidence threshold. The business process cannot stop when that happens. Every AI path in a production payer system needs a defined non-AI path: route to a human queue, apply the prior rules engine, or fail closed with an explicit status. What is not acceptable is an undefined state — a record that silently did not get processed is worse than one the system declined to process. ### Domain-specific evaluation Generic benchmarks measure generic capability. They tell you nothing about whether a model correctly identifies medical necessity criteria, reads a specific payer's policy language, or handles the coding edge cases in your book of business. The evaluation set has to be built from your own adjudicated cases, labeled by people who do the work, and re-run whenever the model, the prompt or the policy changes. This is the most-skipped step and the one that most reliably predicts whether a pilot survives review, because it is the only evidence a compliance reviewer can actually assess. ### Audit-complete observability For a determination that affects coverage, you must be able to reconstruct — months later — which model version, which prompt, which retrieved documents and which input produced it. That is a higher bar than application logging. It means versioned prompts, pinned model identifiers, retained retrieval context and immutable decision records. If any of it lives only in a vendor's platform under their retention policy, your audit trail is a contractual promise rather than a system property. ## What does this cost when the AI layer is rented? Two ways, and the second is the one that stops projects. **Per-seat licensing prices the wrong unit.** Healthcare AI SaaS is typically sold per user per month, but payer workloads are batch-shaped: claims arrive in volume, get processed, and the queue drains. Per-agent and per-seat healthcare AI pricing indexes cost to headcount while the actual work indexes to claim volume. Above a few hundred users the arithmetic favors usage-based or self-hosted deployment by a wide margin, for identical throughput. **PHI leaving the perimeter turns an engineering decision into a legal one.** Once protected health information flows to a third-party API, you need a BAA, you inherit the vendor's retention and subprocessor posture, and every model change becomes a compliance event. Teams routinely lose a quarter to that review — and it is the most common place a technically working pilot stalls. ## How does owning the stack change the outcome? It converts all four properties from vendor features into your own architecture. On ibl.ai you own all the code and the data. The platform is source-available under a perpetual license and runs on your infrastructure, so structured output enforcement, fallback behavior, evaluation harnesses and audit records are components you implement and inspect — not settings you hope are exposed. It is model-agnostic across any LLM, which matters here specifically because model updates are compliance events: pinning a model version for a regulated workflow, and moving off it deliberately after re-evaluation, is only possible when the choice is yours. And because you deploy anywhere — your own cloud, on-premise, or fully air-gapped — PHI never has to cross a boundary you do not control, which removes the review that stalls most pilots. Billing is usage-based with no per-seat pricing, so cost tracks claim volume rather than headcount. 1.6M+ users across 400+ organizations run the platform this way, including NVIDIA, MIT, and Syracuse University. ibl.ai is family-owned and operated from New York, NY — a U.S.-headquartered, domestically-owned long-term partner, not a vendor that sells licenses and moves on. ## How should a payer scope its next AI pilot? Invert the usual order. Most pilots pick an impressive use case and discover the architecture requirements during compliance review, by which point the schedule is gone. Pick a workflow where the output is already structured — eligibility, coding validation, document classification — so the schema is given rather than invented. Build the evaluation set from adjudicated cases before writing any prompts, because that set is what you will defend. Define the non-AI fallback path on day one and test it as a first-class path, not an error handler. Instrument for audit from the first request, since retrofitting decision provenance is materially harder than recording it. Then measure the pilot on production criteria: throughput, cost per processed record, fallback rate, and whether a reviewer can reconstruct a decision. A pilot that scores well on those is one that ships. Related reading: [a reference architecture for healthcare AI](/blog/healthcare-ai-reference-architecture) and [why a BAA alone is not HIPAA compliance](/blog/hipaa-compliant-ai-baa-not-enough). ## Why does owning the AI stack matter? **ibl.ai is the agentic AI platform where you own all the code and the data. You self-host the entire stack inside your own perimeter, run it model-agnostic across any LLM and switch anytime, and pay by usage with no per-seat pricing — so you can deploy anywhere: your cloud, on-premise, GovCloud, or fully air-gapped.** - **You own all the code and the data.** Full source code under a perpetual license, running on your infrastructure. Not API access to someone else's platform — the stack itself is yours. - **Model-agnostic.** Run any LLM — Claude, GPT, Gemini, Llama, Command, or your own fine-tune — and switch providers without rewriting the platform. - **No per-seat pricing.** Usage-based billing against a budget cap you set. Cost tracks what your organization actually uses, not how many people you employ. - **Deploy anywhere.** Your cloud, your VPC, on-premise, GovCloud, or a fully air-gapped network with no outbound connectivity. 1.6M+ users across 400+ organizations run the platform this way, including NVIDIA, MIT, and Syracuse University. ibl.ai is family-owned and operated from New York, NY — a U.S.-headquartered, domestically-owned long-term partner, not a vendor that sells licenses and moves on.